# Ruthenium-Catalyzed *ortho*-Alkenylation of Phenylphosphine Oxides through Regio- and Stereoselective Alkyne Insertion into C–H Bonds

Masaki Itoh,<sup>†</sup> Yuto Hashimoto,<sup>†</sup> Koji Hirano,<sup>†</sup> Tetsuya Satoh,<sup>\*,†,‡</sup> and Masahiro Miura<sup>\*,†</sup>

<sup>†</sup>Department of Applied Chemistry, Faculty of Engineering, Osaka University, Suita, Osaka 565-0871, Japan <sup>‡</sup>JST, ACT-C, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan

**Supporting Information** 

**ABSTRACT:** Direct *ortho*-substitution took place efficiently upon treatment of tri-, di-, and monoarylphosphine oxides with internal alkynes in the presence of a ruthenium catalyst to produce (*o*-alkenylphenyl)phosphine oxides regio- and stereo-selectively. Chemoselective reduction of a product gave the corresponding (*o*-alkenylphenyl)phosphine, which may be useful as a ligand for transition metals.



# INTRODUCTION

Well-designed arylphosphine oxides  $(Ar_nR_{3-n}P=O)$  have attracted considerable attention in organic materials field due to their wide bandgaps and application as host materials in phosphorescent organic light-emitting diodes.<sup>1</sup> They have also been utilized as potential antitumor agents<sup>2</sup> as well as organocatalysts.<sup>3</sup> Furthermore, needless to say, phosphine oxides have been recognized as important intermediates in the preparation of the corresponding phosphine ligands.<sup>4</sup> Therefore, simple methods for their precious synthesis and modification have been continuously needed to be developed in these wide fields.

Meanwhile, the transition-metal-catalyzed ortho C-H bond functionalization of aromatic substrates possessing a directing group has been significantly developed in recent years as atomand step-economical tools in precise organic synthesis.<sup>5</sup> As directing groups, carbonyl, hydroxy, imino, amide, and pyridyl groups have been widely employed to realize regioselective substitution on arenes. Recently, the palladium-,<sup>Sh,m,r,s,w,x</sup> rhodium-,<sup>Sc,f,g,i,o,q</sup> and ruthenium-catalyzed<sup>Sa,b</sup> ortho-alkenylation of aromatic substrates possessing such common directing groups has been explosively developed. Against the recent trend, we have explored new directing groups and found that the P=O function of phenylphosphine oxides can exhibit an effective function to allow the ortho-alkenylation upon treatment of them with alkenes in the presence of a silver salt as oxidant under rhodium catalysis (Scheme 1).<sup>6</sup> This is a rare example of ortho-fuctionalization with the aid of P=O groups,<sup>7</sup> whose coordination abilities toward a transition-metal center have been presumed to be relatively weak. During our further studies on the utilization of this uncommon directing group, we succeeded in finding that a wide range of tri-, di-, and monoarylphosphine oxides efficiently undergo ortho-alkenylation through insertion of alkynes under ruthenium catalysis. Such a ruthenium-catalyzed reaction is attractive because of its lower catalyst cost relative to Rh.8 Furthermore, the present

Scheme 1. Catalytic *ortho*-Alkenylation of Phenylphosphine Oxides



reaction appears to be more environmentally benign because no oxidant such as stoichiometric silver or copper salts is needed. Under the ruthenium catalysis, a similar *ortho*alkylation could also be achieved by using an alkene in place of alkynes.<sup>9</sup> The results obtained with respect to these reactions are described herein.

## RESULTS AND DISCUSSION

In an initial attempt, triphenylphosphine oxide (1a) (0.5 mmol) was treated with diphenylacetylene (2a) (0.25 mmol) in the presence of  $[\text{Ru}(p\text{-cymene})\text{Cl}_2]_2$  (5 mol %), AgSbF<sub>6</sub> (20 mol %), and 1-AdCO<sub>2</sub>H (Ad = adamantyl) (1 mmol) in dioxane at 100 °C for 3 h. As a result, *ortho*-alkenylated product **3aa** was obtained in 74% yield (Table 1, entry 1). In this case, formation of multiply alkenylated products was also detected. To our delight, **3aa** was obtained quantitatively by using an excess amount of **1a** (entry 2). It was confirmed that the

**Received:** June 28, 2013 **Published:** July 24, 2013 Table 1. Reaction of Triphenylphosphine Oxide (1a) with Diphenylacetylene  $(2a)^a$ 

Ph Ph−P <sup>∽O</sup>	Ph	[Ru( <i>p</i> -cymene)Cl <sub>2</sub> ] <sub>2</sub> (5 mo AgSbF <sub>6</sub> (20 mol%)	ol%) Ph Ph−P <sup>≠O</sup> Ph → ↓ ↓ Ph
	Ph	acid/dioxane, 100 °C	
1a	2a		3aa
entry	acid		yield of <b>3aa</b> $(\%)^b$
1 <sup>c</sup>	1-AdCO <sub>2</sub> H		74
2	1-AdCO <sub>2</sub> H		>99 (82)
3 <sup>d</sup>	1-AdCO <sub>2</sub> H		0
$4^e$	1-AdCO <sub>2</sub> H		0
5	AcOH		97 (86)
6	PivOH		>99
7	2,6-Me <sub>2</sub> C <sub>6</sub> H <sub>3</sub> CO <sub>2</sub> H		95

<sup>*a*</sup>Reaction conditions: **1a** (1.25 mmol), **2a** (0.25 mmol),  $[Ru(p-cymene)Cl_2]_2$  (0.013 mmol), AgSbF<sub>6</sub> (0.05 mmol), acid (1 mmol) in dioxane (3 mL) under N<sub>2</sub> at 100 °C for 3 h. <sup>*b*</sup>GC yield based on the amount of **2a** used. Value in parentheses indicates yield after purification. <sup>*c*</sup>With **1a** (0.5 mmol). <sup>*d*</sup>Without  $[Ru(p-cymene)Cl_2]_2$ . <sup>*c*</sup>Without AgSbF<sub>6</sub>.

reaction did not proceed at all without  $[Ru(p-cymene)Cl_2]_2$  (entry 3) or AgSbF<sub>6</sub> (entry 4). Other acids such as AcOH, PivOH, and 2,6-dimethylbenzoic acid were found to be comparably effective as 1-AdCO<sub>2</sub>H (entries 5–7). Therefore, we decided to use the cheapest acid, AcOH, in further experiments.

The reactions of various arylphosphine oxides 1b-n with 2a were next examined under conditions using AcOH. A series of tris(*p*-substituted phenyl)phosphine oxides 1b-f underwent alkenylation to produce 3ba-3fa in good yields (Table 2, entries 1-5). Although the reaction of 1f was relatively sluggish, the corresponding product 3fa was obtained in 80% yield by extending the reaction time to 24 h under refluxing conditions (entry 5). While tris(m-tolyl) phosphine oxide (1g) underwent the reaction smoothly, the reaction of *m*-chlorinated substrate 1h required 18 h to be completed (entries 6 and 7). Even sterically hindered tris(o-tolyl)phosphine oxide (1i) coupled with 2a efficiently to produce 3ia in 77% yield (entry 8). Similarly to triarylphosphine oxides, alkyl(diphenyl)phosphine oxides 1j,k and dialkyl(phenyl)phosphine oxides 11,m also underwent ortho-alkenylation (entries 9–12). Note that the oxide of CyJohnPhos (1n) could be employed as the substrate to produce 3na in an excellent yield (entry 13). Only in the last case, the product was formed as an E/Z mixture.

The reactions of various internal alkynes 2b-j with 1a were also examined. Bis(p-substituted phenyl)acetylenes underwent the coupling with 1a to give 3ab-3ae in 90-98% yields (Table 3, entries 1-4). The reaction of di(2-thienyl)acetylene (2f) took place under similar conditions, albeit with low efficiency (entry 5). It would be possible that some interaction between the thienyl moiety and Ru retarded the reaction. Unsymmetrical alkyl(phenyl)acetylenes 2g-i and phenyl-(trimethylsilyl)acetylene (2j) could also be used as alkenyl sources to afford 3ag-3aj stereo- and regioselectively (entries 6-9). Other isomers were not detected at all. The reaction of 2j proceeded involving desilylation to form 3aj as a single major product (entry 9). In contrast to internal alkynes, the reactions with terminal alkynes were found to be inefficient. Under similar conditions, the reaction of 1a with (triisopropylsilyl)acetylene gave only a trace amount of alkenylated product. In

Table 2. Reaction of Arylphosphine Oxides 1 with  $2a^{a}$ 



<sup>*a*</sup>Reaction conditions: **1** (1.25 mmol), **2a** (0.25 mmol), [Ru(*p*-cymene)Cl<sub>2</sub>]<sub>2</sub> (0.013 mmol), AgSbF<sub>6</sub> (0.05 mmol), AcOH (1 mmol) in dioxane (3 mL) at 100 °C under N<sub>2</sub> <sup>*b*</sup>Isolated yield. <sup>*c*</sup>In refluxing dioxane (bath temperature: 120 °C). <sup>*d*</sup>E/Z = 84:16.

the case using phenylacetylene, any coupling products could not be detected at all. In both cases, significant amounts of substrates remained unconsumed.

Chemoselective reduction methods from phosphine oxides to the corresponding phosphines have been established.<sup>10</sup> As a



Table 3. Reaction of 1a with Alkynes  $2^{a}$ 

<sup>*a*</sup>Reaction conditions: **1a** (1.25 mmol), **2** (0.25 mmol),  $[Ru(p-cymene)Cl_2]_2$  (0.013 mmol), AgSbF<sub>6</sub> (0.05 mmol), AcOH (1 mmol) in dioxane (3 mL) at 100 °C under N<sub>2</sub>. <sup>*b*</sup>Isolated yield.

preliminary attempt, we examined the reduction of one of our alkenylated product **3aj** by the Beller's procedure using  $(4-NO_2C_6H_4O)_2P(O)OH/(EtO)_2MeSiH.^{10a}$  As a result, we succeeded in obtaining diphenyl(*o*-styrylphenyl)phosphine (4), as shown in Scheme 2. It is well-known that (*o*-substituted

#### Scheme 2. Reduction of 3aj



phenyl)phosphines are useful as ligands for transition-metals.<sup>11</sup> The reduction of more sterically hindered **3aa** also proceeded to some extent under similar conditions. However, considerable contamination of an isomer of product was observed by GC–MS.

The *ortho*-alkenylation of **1** seems to proceed via *ortho*metalation, alkyne insertion, and protonolysis, as shown in Scheme 3. The added acid may promote the last step.<sup>12</sup> The *ortho*-metalation on parent triphenylphosphine itself has been reported to produce a four-membered ruthenacycle.<sup>13</sup> Unfortunately, its treatment with **2a** under our standard conditions did not give any *ortho*-alkenylated product at all.





For providing further mechanistic information, the reaction of deuterated dicyclohexyl(phenyl)phosphine oxide  $(11-d_5)$  with **2a** was conducted under standard conditions (Scheme 4). In the early stage (3 h), deuterium incorporation at the





alkenyl position of the product was not detected at all by <sup>1</sup>H NMR. This result appears to exclude the possibility of a reaction route involving initial oxidative addition of an *ortho* C–H bond, which should result in deuterium incorporation at the position. During the reaction, no significant D–H exchange at the *ortho*-positions of recovered  $11-d_5$  as well as at the 6-position of product  $31a-d_4$  was observed. More informative is that the reaction rate of  $11-d_5$  was considerably lower than that of  $11-d_0$ . Thus, the kinetic isotope effect was determined to be 2.1. These observations suggest that the *ortho* C–H bond cleavage step to form intermediate A is likely irreversible and involved as the rate-determining step.

Under similar conditions, *ortho*-alkylation of phosphine oxide **1a** using butyl acrylate (**5**) in place of alkynes was finally examined. Treatment of **1a** (0.5 mmol) with **5** (0.25 mmol) in the presence of  $[\text{Ru}(p\text{-cymene})\text{Cl}_2]_2$  (5 mol %), AgSbF<sub>6</sub> (20 mol %), and 1-AdCO<sub>2</sub>H (1 mmol) in dioxane at 100 °C for 5 h gave alkylated product **6** in 33% yield (Scheme 5). At 120 °C in diglyme, the yield of **6** was improved to 58%.

#### CONCLUSIONS

We have demonstrated that various arylphosphine oxides undergo *ortho*-alkenylation on treatment with alkynes under ruthenium catalysis through P==O group-directed C-H bond

#### Scheme 5. ortho-Alkylation of 1a with Butyl Acrylate (6)



# The Journal of Organic Chemistry

cleavage. The relevant alkylation with an acrylate ester has also been achieved. Work is underway toward further utilization of related phosphorus-containing groups.

## EXPERIMENTAL SECTION

**General.** H and <sup>13</sup>C NMR spectra were recorded at 400 or 600 and 100 or 150 MHz, respectively, for CDCl<sub>3</sub> solutions. HRMS data were obtained by EI using a double focusing mass spectrometer, unless noted. GC analysis was carried out using a silicon OV-17 column (i.d. 2.6 mm  $\times$  1.5 m). GC–MS analysis was carried out using a CBP-1 capillary column (i.d. 0.25 mm  $\times$  25 m). The structures of all products listed below were unambiguously determined by <sup>1</sup>H, <sup>13</sup>C, and <sup>31</sup>P NMR with the aid of NOE, COSY, HSQC, and HMBC experiments.

Phosphine oxides 1b-n and dicyclohexyl( $d_5$ -phenyl)phosphine oxide ( $1l-d_5$ ) were prepared as noted below. Diarylacetylenes  $2b-f^{14}$  and 1-cyclopropyl-2-phenylacetylene (2i)<sup>15</sup> were prepared according to published procedures. Phosphine oxides 4a-c were prepared as noted below. Other reagents were commercially available.

**Preparation of Phosphine Oxides 1.** Synthesis of 1b is representative. To a solution of tris(p-tolyl)phosphine (5 mmol, 1.52 g) in THF (5 mL) was dropped slowly  $H_2O_2$  (30% aqueous solution, 3 equiv), and the mixture was stirred at room temperature. The exothermic reaction terminated within a few minutes. After the consumption of phosphine was checked by TLC, the reaction mixture was quenched by saturated NaHCO<sub>3</sub> (10 mL) and saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (20 mL) and additionally stirred for a few minutes. Then, the reaction mixture was extracted by ethyl acetate (20 mL, three times) and dried over Na<sub>2</sub>SO<sub>4</sub>. Volatiles were removed in vacuo to afford tris(p-tolyl)phosphine oxide (1b) quantitatively without further purification.

General Procedure for the Reaction of Phosphine Oxides 1 with Alkynes 2. To a 20 mL two-necked flask with a reflux condenser, a balloon filled with N<sub>2</sub>, and a rubber septum were added phosphine oxide 1 (1.25 mmol), alkyne 2 (0.25 mmol), [Ru(p $cymene)Cl_2]_2$  (0.013 mmol, 7.7 mg), AgSbF<sub>6</sub> (0.05 mmol, 17 mg), AcOH (1 mmol, 60 mg), 1-methylnaphthalene (ca. 40 mg) as internal standard, and dioxane (3 mL). Then, the resulting mixture was stirred under nitrogen at 100 °C for 3–40 h. After cooling, the reaction mixture was extracted with ethyl acetate (100 mL). The organic layer was washed with water (100 mL, three times) and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvents under vacuum, product 3 was isolated by column chromatography on silica gel using hexane/ethyl acetate (1:1, v/v) as eluent.

**Procedure for Reduction of Phosphine Oxide 3aj.**<sup>10a</sup> To a 20 mL two-necked flask with a reflux condenser, a balloon filled with N<sub>2</sub>, and a rubber septum were added phosphine oxide **3aj** (0.25 mmol, 95 mg), bis(4-nitrophenyl)phosphate (0.038 mmol, 13 mg), diethoxymethylsilane (1 mmol, 134 mg), 1-methylnaphthalene (ca. 30 mg) as internal standard, and toluene (2 mL). After the solution stirred under nitrogen at 110 °C for 24 h, the reaction mixture was cooled to 0 °C, and 3 N methanolic KOH (5 mL) was added slowly. Then, the reaction mixture was extracted with ethyl acetate (100 mL). The organic layer was washed with 1 N HCl (5 mL) and saturated NaHCO<sub>3</sub> (5 mL), and dried over Na<sub>2</sub>SO<sub>4</sub>. Concentration in vacuo followed by column chromatography on silica gel using hexane/ethyl acetate (20:1, v/v) as eluent gave phosphine **4** (60 mg, 0.16 mmol) in 66% yield.

**Procedure for Reaction of Deuterated Substrate 11-***d***<sub>5</sub>. To a 20 mL two-necked flask were added dicyclohexyl(***d***<sub>5</sub>-phenyl)-phosphine oxide (11-***d***<sub>5</sub>) (1.25 mmol), diphenylacetylene (2a) (0.25 mmol), [Ru(***p***-cymene)Cl<sub>2</sub>]<sub>2</sub> (0.0125 mmol), AgSbF<sub>6</sub> (0.05 mmol), AcOH (1 mmol), 1-methylnaphthalene (ca. 30 mg) as internal standard, and dioxane (3 mL). The resulting mixture was stirred under N<sub>2</sub> at 100 °C for 5 h. After cooling, the reaction mixture was extracted with ethyl acetate (100 mL), washed with water (100 mL, three times), and dried over Na<sub>2</sub>SO<sub>4</sub>. Produced <b>3la**-*d*<sub>4</sub> and recovered **1l**-*d*<sub>5</sub> were isolated by column chromatography on silica gel using ethyl acetate as eluant. Recoverd **1l**-*d*<sub>5</sub> (305 mg, 1.03 mmol); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.09–1.35 (m, 10H), 1.60–1.82 (m, 8H), 1.99–2.06 (m, 4H), 7.67 (d, *J* = 9.7 Hz, 0.06H). Produced **3la**-*d*<sub>4</sub> (30 mg, 25%);

<sup>1</sup>H NMR (400 MHz,  $CDCl_3$ )  $\delta$  0.93–1.35 (m, 10H), 1.55–1.84 (m, 12H), 6.57 (s, 1H), 7.15–7.26 (m, 10H), 8.06 (d, *J* = 11.4 Hz, 0.04H).

(*E*)-[2-(1,2-Diphenylethenyl)phenyl]diphenylphosphine Oxide (3aa). Mp 68–69 °C (colorless powder), 98 mg (86%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.72 (d, *J* = 6.0 Hz, 2H), 6.83 (s, 1H), 6.99–7.25 (m, 10H), 7.32–7.44 (m, 8H), 7.73 (dd, *J* = 7.3, 11.9 Hz, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  126.3 (d, *J* = 12.4 Hz), 126.6, 127.1, 127.5, 127.8, 128.2 (d, *J* = 12.5 Hz), 129.7, 130.6, 131.2 (d, *J* = 2.9 Hz), 131.3 (d, *J* = 2.8 Hz), 131.6 (d, *J* = 9.5 Hz), 131.9 (d, *J* = 102.5 Hz), 132.0 (d, *J* = 9.6 Hz), 133.9 (d, *J* = 104.5 Hz), 134.1, 134.6 (d, *J* = 12.5 Hz), 136.8, 140.1 (d, *J* = 3.9 Hz), 140.2, 149.6 (d, *J* = 8.6 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  28.97; HRMS *m*/*z* calcd for C<sub>32</sub>H<sub>25</sub>OP (M<sup>+</sup>) 456.1643, found 456.1646.

(*E*)-[2-(1,2-Diphenylethenyl)-4-methylphenyl]bis(4methylphenyl)phosphine Oxide (3ba). Mp 160–161 °C (colorless powder), 105 mg (85%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.27 (s, 3H), 2.32 (s, 6H), 6.72–6.75 (m, 3H), 6.97–7.04 (m, 5H), 7.07–7.14 (m, 9H), 7.28 (dd, *J* = 7.8, 13.7 Hz, 1H), 7.59 (dd, *J* = 8.2, 11.8 Hz, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  21.3, 21.4, 126.5, 126.9, 127.1 (d, *J* = 13.4 Hz), 127.4, 127.8, 128.9 (d, *J* = 12.5 Hz), 129.2 (d, *J* = 104.5 Hz), 129.6, 130.5, 131.1 (d, *J* = 107.5 Hz), 131.6 (d, *J* = 9.6 Hz), 132.5 (d, *J* = 9.5 Hz), 133.7, 134.7 (d, *J* = 12.4 Hz), 137.0, 140.1 (d, *J* = 3.8 Hz), 140.3, 141.3 (d, *J* = 2.9 Hz), 141.5 (d, *J* = 2.9 Hz), 149.3 (d, *J* = 7.6 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  28.83; HRMS *m*/*z* calcd for C<sub>35</sub>H<sub>31</sub>OP (M<sup>+</sup>) 498.2113, found 498.2112.

(*E*)-[2-(1,2-Diphenylethenyl)-4-methoxyphenyl]bis(4methoxyphenyl)phosphine Oxide (3ca). Mp 153–154 °C (colorless powder), 126 mg (92%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.71 (s, 3H), 3.77 (s, 6H), 6.68–6.69 (m, 1H), 6.73–6.79 (m, 4H), 6.84 (dd, *J* = 2.3, 8.7 Hz, 4H), 6.99–7.13 (m, 8H), 7.32 (dd, *J* = 8.5, 13.5 Hz, 1H), 7.61 (d, *J* = 8.7, 11.2 Hz, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  55.16, 55.20, 111.5 (d, *J* = 13.4 Hz), 113.7 (d, *J* = 13.4 Hz), 117.6 (d, *J* = 10.5 Hz), 124.3 (d, *J* = 108.3 Hz), 125.9 (d, *J* = 111.2 Hz), 126.6, 127.1, 127.4, 127.8, 129.7, 130.5, 133.3 (d, *J* = 10.5 Hz), 133.7, 136.5 (d, *J* = 14.3 Hz), 136.9, 139.8 (d, *J* = 3.8 Hz), 140.1, 151.3 (d, *J* = 8.6 Hz), 161.5 (d, *J* = 2.8 Hz), 161.7 (d, *J* = 2.8 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  28.12; HRMS *m*/*z* calcd for C<sub>35</sub>H<sub>31</sub>O<sub>4</sub>P (M<sup>+</sup>) 546.1960, found 546.1954.

(*E*)-[4-Chloro-2-(1,2-diphenylethenyl)phenyl]bis(4chlorophenyl)phosphine Oxide (3da). Mp 73–74 °C (colorless powder), 119 mg (85%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.72 (s, 1H), 6.76–6.78 (m, 2H), 7.03–7.29 (m, 11H), 7.33 (dd, *J* = 2.3, 8.3 Hz, 4H), 7.59 (dd, *J* = 8.3, 11.0 Hz, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ 126.8 (d, *J* = 13.4 Hz), 127.2, 127.6, 127.7, 128.1, 128.8 (d, *J* = 12.5 Hz), 129.53, 129.54 (d, *J* = 105.4 Hz), 130.4, 131.6 (d, *J* = 106.4 Hz), 132.2 (d, *J* = 10.5 Hz), 132.8 (d, *J* = 10.6 Hz), 134.7, 135.6 (d, *J* = 14.4 Hz), 136.1, 138.2 (d, *J* = 4.8 Hz), 138.3 (d, *J* = 3.8 Hz), 138.7 (d, *J* = 3.8 Hz), 139.0, 151.3 (d, *J* = 8.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$ 27.21; HRMS *m*/*z* calcd for C<sub>32</sub>H<sub>22</sub>Cl<sub>3</sub>OP (M<sup>+</sup>) 558.0474, found 558.0477.

(*E*)-[2-(1,2-Diphenylethenyl)-4-fluorophenyl]bis(4-fluorophenyl)phosphine Oxide (3ea). Mp 67–68 °C (colorless powder), 106 mg (83%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.77 (d, *J* = 6.8 Hz, 2H), 6.81 (s, 1H), 6.88–7.17 (m, 14H), 7.34 (ddd, *J* = 5.9, 8.6, 14.5 Hz, 1H), 7.68 (ddd, *J* = 5.9, 7.7, 11.3 Hz, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  113.8 (dd, *J* = 13.4, 21.0 Hz), 115.8 (dd, *J* = 13.4, 21.0 Hz), 119.3 (dd, *J* = 10.5, 21.0 Hz), 127.2, 127.5 (dd, *J* = 3.8, 106.8 Hz), 127.6, 127.7, 128.1, 129.5 (dd, *J* = 3.8, 108.7 Hz), 129.6, 130.4, 133.9 (dd, *J* = 1.9, 3.8 Hz), 139.3, 152.8 (dd, *J* = 8.6, 8.6 Hz), 164.4 (dd, *J* = 2.9, 254.6 Hz), 164.7 (dd, *J* = 2.9, 253.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  26.88; HRMS *m*/*z* calcd for C<sub>32</sub>H<sub>22</sub>F<sub>3</sub>OP (M<sup>+</sup>) 510.1360, found 510.1358.

(*E*)-[2-(1,2-Diphenylethenyl)-4-(trifluoromethyl)phenyl]bis-[4-(trifluoromethyl)phenyl]phosphine Oxide (3fa). Mp 70–71 °C (pale yellow powder), 131 mg (80%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.71–6.74 (m, 3H), 7.03–7.19 (m, 8H), 7.43–7.58 (m, 3H), 7.63 (dd, *J* = 2.3, 8.3 Hz, 4H), 7.82 (dd, *J* = 8.3, 11.5 Hz, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  123.2 (q, *J* = 273.1 Hz), 123.4 (q, *J* = 273.1 Hz), 123.5 (dq, *J* = 2.9, 13.4 Hz), 125.5 (dq, *J* = 2.8, 11.5 Hz), 127.6, 127.8, 128.1, 128.3, 129.1 (dq, J = 2.9, 10.6 Hz), 129.5, 130.4, 131.9 (d, J = 9.6 Hz), 133.8 (dq, J = 2.9, 32.6 Hz), 133.9 (dq, J = 2.9, 33.6 Hz), 134.9 (d, J = 13.4 Hz), 135.3 (d, J = 102.5 Hz), 135.4, 136.8 (d, J = 101.6 Hz), 137.3 (d, J = 1.9 Hz), 138.6, 138.8 (d, J = 2.8 Hz), 150.8 (d, J = 7.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  26.45; HRMS m/z calcd for C<sub>35</sub>H<sub>22</sub>F<sub>9</sub>OP (M<sup>+</sup>) 660.1265, found 660.1259.

(*E*)-[2-(1,2-Diphenylethenyl)-5-methylphenyl]bis(3methylphenyl)phosphine Oxide (3ga). Mp 203–204 °C (colorless powder), 110 mg (88%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.21 (s, 6H), 2.25 (s, 3H), 6.68 (dd, *J* = 2.2, 7.3 Hz, 2H), 6.91 (s, 1H), 6.99– 7.14 (m, 9H), 7.18–7.27 (m, 6H), 7.49 (dd, *J* = 7.3, 11.8 Hz, 2H), 7.63 (d, *J* = 11.8 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  21.2, 21.3, 126.5, 127.1, 127.4, 127.8, 128.0 (d, *J* = 12.4 Hz), 128.5 (d, *J* = 9.5 Hz), 129.8, 130.6, 131.8 (d, *J* = 2.9 Hz), 131.9 (d, *J* = 9.5 Hz), 132.0 (d, *J* = 2.8 Hz), 132.1 (d, *J* = 102.0 Hz), 132.3 (d, *J* = 8.5 Hz), 133.9 (d, *J* = 103.0 Hz), 134.1, 135.2 (d, *J* = 12.4 Hz), 136.2 (d, *J* = 12.4 Hz), 136.9, 138.1 (d, *J* = 11.4 Hz), 139.7 (d, *J* = 3.8 Hz), 140.6, 146.6 (d, *J* = 7.6 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  28.81; HRMS *m*/*z* calcd for C<sub>35</sub>H<sub>31</sub>OP (M<sup>+</sup>) 498.2113, found 498.2115.

(*E*)-[5-Chloro-2-(1,2-diphenylethenyl)phenyl]bis(3chlorophenyl)phosphine Oxide (3ha). Mp 73–74 °C (colorless powder), 109 mg (78%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.73 (dd, *J* = 1.8, 7.7 Hz, 2H), 6.89 (s, 1H), 7.03–7.17 (m, 9H), 7.28–7.34 (m, 3H), 7.40–7.44 (m, 3H), 7.57 (dd, *J* = 7.7, 11.3 Hz, 2H), 7.69 (d, *J* = 12.2 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  127.2, 127.69, 127.74, 128.1, 129.5 (d, *J* = 9.5 Hz), 129.6, 130.0 (d, *J* = 12.4 Hz), 130.5, 131.2 (d, *J* = 9.6 Hz), 131.97 (d, *J* = 2.8 Hz), 132.01 (d, *J* = 3.9 Hz), 132.8 (d, *J* = 102.0 Hz), 133.0 (d, *J* = 16.2 Hz), 133.9 (d, *J* = 8.6 Hz), 134.0 (d, *J* = 12.4 Hz), 134.90 (d, *J* = 103.0 Hz), 134.92, 135.1 (d, *J* = 15.3 Hz), 136.1, 138.7 (d, *J* = 3.8 Hz), 139.4, 148.1 (d, *J* = 6.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  26.02; HRMS *m*/*z* calcd for C<sub>32</sub>H<sub>22</sub>Cl<sub>3</sub>OP (M<sup>+</sup>) 558.0474, found 558.0471.

(*E*)-[2-(1,2-Diphenylethenyl)-6-methylphenyl]bis(2methylphenyl)phosphine Oxide (3ia). Mp 91–92 °C (pale yellow powder), 96 mg (77%); <sup>1</sup>H NMR (600 MHz, DMSO- $d_{6j}$  100 °C)  $\delta$ 1.83 (s, 3H), 2.37 (s, 6H), 6.08 (s, 1H), 6.79 (dd, *J* = 1.5, 7.3 Hz, 2H), 6.98–7.02 (m, 3H), 7.07–7.14 (m, 6H), 7.17–7.21 (m, 3H), 7.25 (dd, *J* = 4.1, 7.6 Hz, 2H), 7.32 (d, *J* = 6.2 Hz, 2H), 7.40 (tt, *J* = 1.5, 7.3 Hz, 2H), 7.43 (dt, *J* = 1.5, 7.9 Hz, 1H); <sup>13</sup>C NMR (150 MHz, DMSO- $d_{6j}$ 100 °C)  $\delta$  20.3 (d, *J* = 4.0 Hz), 22.9 (d, *J* = 3.9 Hz), 124.9 (d, *J* = 12.9 Hz), 125.7, 126.2, 126.8, 126.9, 128.2, 129.2 (d, *J* = 9.9 Hz), 129.3, 129.7 (d, *J* = 102.9 Hz), 130.0 (d, *J* = 9.9 Hz), 130.07, 130.11 (d, *J* = 3.0 Hz), 130.8 (d, *J* = 2.9 Hz), 131.1 (d, *J* = 9.9 Hz), 131.2 (d, *J* = 102.9 Hz), 131.4 (d, *J* = 12.9 Hz), 136.9, 140.0, 140.9 (d, *J* = 9.9 Hz), 141.9, 142.9 (d, *J* = 4.0 Hz), 150.5 (d, *J* = 6.9 Hz); <sup>31</sup>P NMR (243 MHz, DMSO- $d_6$ )  $\delta$  34.64; HRMS *m*/*z* calcd for C<sub>35</sub>H<sub>31</sub>OP (M<sup>+</sup>) 498.2113, found 498.2108.

(*E*)-[2-(1,2-Diphenylethenyl)phenyl](methyl)(phenyl)phosphine Oxide (3ja). Mp 149–150 °C (brown powder), 73 mg (74%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.03 (d, *J* = 12.8 Hz, 3H), 6.57 (s, 1H), 6.89–6.91 (m, 2H), 6.96 (dd, *J* = 1.8, 8.2 Hz, 2H), 7.09–7.19 (m, 7H), 7.32 (dt, *J* = 2.8, 7.3 Hz, 2H), 7.38–7.45 (m, 3H), 7.54–7.59 (m, 2H), 7.96–8.02 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  17.5 (d, *J* = 74.8 Hz), 126.9 (d, *J* = 11.5 Hz), 127.1, 127.5, 127.9, 128.1, 128.3 (d, *J* = 11.5 Hz), 129.6, 130.3, 130.5 (d, *J* = 10.5 Hz), 131.1 (d, *J* = 1.9 Hz), 131.3 (d, *J* = 1.9 Hz), 131.9 (d, *J* = 9.6 Hz), 132.6 (d, *J* = 90.1 Hz), 133.0 (d, *J* = 10.5 Hz), 135.6 (d, *J* = 102.5 Hz), 136.4, 139.9, 140.00, 140.04, 148.2 (d, *J* = 8.6 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$ 31.54; HRMS *m*/*z* calcd for C<sub>27</sub>H<sub>23</sub>OP (M<sup>+</sup>) 394.1487, found 394.1487.

(*E*)-Cyclohexyl[2-(1,2-diphenylethenyl)phenyl](phenyl)phosphine Oxide (3ka). Mp 71–72 °C (colorless powder), 105 mg (91%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.13–1.23 (m, 3H), 1.53–1.81 (m, 7H), 2.25–2.26 (m, 1H), 6.21 (s, 1H), 6.92–6.94 (m, 4H), 7.06– 7.15 (m, 7H), 7.26–7.30 (m, 2H), 7.37–7.46 (m, 3H), 7.51–7.56 (m, 2H), 8.06–8.11 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  25.0 (d, *J* = 2.9 Hz), 25.4 (d, *J* = 2.9 Hz), 25.8, 26.3 (d, *J* = 13.4 Hz), 26.4 (d, *J* = 14.3 Hz), 36.9 (d, *J* = 73.5 Hz), 126.7 (d, *J* = 10.5 Hz), 126.9, 127.2, 127.8, 127.9, 128.1 (d, *J* = 11.5 Hz), 129.6, 130.4, 130.8 (d, *J* = 2.8 Hz), 130.9 (d, *J* = 1.9 Hz), 131.09 (d, *J* = 90.6 Hz), 131.14 (d, *J* = 8.5 Hz), 131.9, 132.2 (d, J = 9.5 Hz), 132.9 (d, J = 8.6 Hz), 133.6 (d, J = 94.4 Hz), 136.7, 139.8, 141.0 (d, J = 2.9 Hz), 148.7 (d, J = 7.6 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  35.99; HRMS m/z calcd for C<sub>32</sub>H<sub>31</sub>OP (M<sup>+</sup>) 462.2113, found 462.2111.

(*E*)-Dicyclohexyl[2-(1,2-diphenylethenyl)phenyl]phosphine Oxide (3la). Mp 32–33 °C (brown powder), 96 mg (82%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.93–1.36 (m, 10H), 1.55–1.84 (m, 12H), 6.57 (s, 1H), 7.15–7.25 (m, 10H), 7.37 (ddd, *J* = 1.4, 4.1, 7.3 Hz, 1H), 7.46 (tt, *J* = 1.4, 7.8 Hz, 1H), 7.51 (tt, *J* = 1.4, 7.3 Hz, 1H), 8.06 (ddd, *J* = 1.4, 7.8, 11.0 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 25.6 (d, *J* = 1.9 Hz), 26.1 (d, *J* = 3.8 Hz), 26.2 (d, *J* = 3.8 Hz), 26.3 (d, *J* = 12.5 Hz), 26.4 (d, *J* = 12.5 Hz), 37.4 (d, *J* = 65.1 Hz), 127.1, 127.2 (d, *J* = 9.6 Hz), 127.8, 128.2, 128.29, 128.33, 130.4, 130.5 (d, *J* = 78.6 Hz), 130.6 (d, *J* = 2.9 Hz), 130.8, 132.7 (d, *J* = 9.6 Hz), 134.6 (d, *J* = 6.7 Hz), 136.9, 139.0, 142.8 (d, *J* = 2.9 Hz), 145.5 (d, *J* = 8.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>) δ 48.28; HRMS *m*/*z* calcd for C<sub>32</sub>H<sub>37</sub>OP (M<sup>+</sup>) 468.2582, found 468.2590.

(*E*)-Di-*tert*-butyl[2-(1,2-diphenylethenyl)phenyl]phosphine Oxide (3ma). Mp 129–130 °C (brown powder), 46 mg (44%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.15 (d, *J* = 13.1 Hz, 18H), 6.43 (s, 1H), 7.06–7.16 (m, 8H), 7.30–7.37 (m, 3H), 7.49–7.60 (m, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  27.4, 37.2 (d, *J* = 59.1 Hz), 125.2 (d, *J* = 11.4 Hz), 126.2, 126.3, 127.0, 127.8, 127.9, 129.0 (d, *J* = 76.3 Hz), 129.2, 130.2 (d, *J* = 2.9 Hz), 130.7, 131.6 (d, *J* = 11.4 Hz), 133.4 (d, *J* = 8.6 Hz), 137.8, 140.3, 143.2 (d, *J* = 2.9 Hz), 150.5 (d, *J* = 3.8 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  53.48; HRMS *m*/*z* calcd for C<sub>28</sub>H<sub>33</sub>OP (M<sup>+</sup>) 416.2269, found 416.2266.

(*E*)-Dicyclohexyl[3-(1,2-diphenylethenyl)-[1,1'-biphenyl]-2yl]phosphine Oxide (3na). (*E*:*Z* = 84:16) 133 mg (98%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.74–1.62 (m, 22H), 6.47 (s, 0.84H, *E*), 6.74 (s, 0.16H, *Z*), 7.06–7.19 (m, 7H), 7.22–7.30 (m, 4H), 7.34–7.47 (m, 7H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, 40 °C)  $\delta$  25.7 (d, *J* = 1.9 Hz), 26.5 (d, *J* = 2.9 Hz), 26.6 (d, *J* = 3.8 Hz), 26.7 (d, *J* = 13.4 Hz, overlapped), 39.8 (d, *J* = 66.2 Hz), 126.2, 126.6, 127.4, 127.5 (d, *J* = 3.8 Hz), 127.7, 127.8, 129.1, 129.3 (d, *J* = 2.8 Hz), 129.5, 129.7 (d, *J* = 74.7 Hz), 129.8, 130.9 (d, *J* = 9.6 Hz), 131.2, 132.5 (d, *J* = 8.6 Hz), 137.8, 138.0, 140.7, 143.3 (d, *J* = 2.9 Hz), 144.6 (d, *J* = 2.9 Hz), 145.0; <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  50.86 (*Z*), 51.40 (*E*); HRMS *m*/*z* calcd for C<sub>38</sub>H<sub>41</sub>OP (M<sup>+</sup>) 544.2895, found 544.2897.

(*E*)-{2-[1,2-Bis(4-methylphenyl)ethenyl]phenyl}diphenylphosphine Oxide (3ab). Mp 68–69 °C (colorless powder), 110 mg, 91%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  2.23 (s, 3H), 2.26 (s, 3H), 6.63 (d, *J* = 7.8 Hz, 2H), 6.80 (s, 1H), 6.83 (d, *J* = 7.8 Hz, 2H), 6.89–6.94 (m, 4H), 7.14–7.17 (m, 1H), 7.19–7.23 (m, 1H), 7.31–7.44 (m, 8H), 7.69–7.75 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  21.2 (overlapped), 126.2 (d, *J* = 13.4 Hz), 128.18 (d, *J* = 11.5 Hz), 128.19, 128.6, 129.6, 130.4, 131.1 (d, *J* = 1.9 Hz), 131.2 (d, *J* = 2.9 Hz), 131.6 (d, *J* = 9.6 Hz), 131.8 (d, *J* = 101.6 Hz), 132.0 (d, *J* = 9.5 Hz), 133.8, 133.99 (d, *J* = 103.5 Hz), 134.04, 134.7 (d, *J* = 12.5 Hz), 136.3, 136.7, 137.5, 139.2 (d, *J* = 3.8 Hz), 150.0 (d, *J* = 7.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  28.83; HRMS *m*/*z* calcd for C<sub>34</sub>H<sub>29</sub>OP (M<sup>+</sup>) 484.1956, found 484.1960.

(E)-[2-{1,2-Bis[4-(*tert*-butyl)phenyl] ethenyl}phenyl]diphenylphosphine Oxide (3ac). Mp 69–70 °C (colorless powder), 128 mg (90%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.25 (s, 9H), 1.28 (s, 9H), 6.69 (d, *J* = 8.3 Hz, 2H), 6.75 (s, 1H), 6.99 (d, *J* = 8.7 Hz, 2H), 7.03 (d, *J* = 8.7 Hz, 2H), 7.13 (d, *J* = 8.7 Hz, 2H), 7.17– 7.23 (m, 2H), 7.32 (dt, *J* = 2.8, 7.8 Hz, 4H), 7.37–7.42 (m, 4H), 7.68–7.73 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  31.2, 31.3, 34.4 (overlapped), 124.4, 124.7, 126.1 (d, *J* = 12.5 Hz), 128.1 (d, *J* = 11.5 Hz), 129.3, 129.8, 131.1 (d, *J* = 1.9 Hz), 131.2 (d, *J* = 2.9 Hz), 131.6 (d, *J* = 103.5 Hz), 131.7 (d, *J* = 8.7 Hz), 132.0 (d, *J* = 8.6 Hz), 133.86, 133.92, 134.0 (d, *J* = 103.5 Hz), 134.6 (d, *J* = 12.4 Hz), 137.2, 138.9 (d, *J* = 3.8 Hz), 149.6, 149.8, 150.1 (d, *J* = 7.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  28.93; HRMS *m*/*z* calcd for C<sub>40</sub>H<sub>41</sub>OP (M<sup>+</sup>) 568.2895, found 568.2898.

(*E*)-{2-[1,2-Bis(4-chlorophenyl)ethenyl]phenyl}diphenylphosphine Oxide (3ad). Mp 74–75 °C (colorless powder), 121 mg (92%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.64 (s, 1H), 6.70 (d, *J* = 8.2 Hz, 2H), 7.01–7.07 (m, 6H), 7.17 (dd, *J* = 4.1, 7.3 Hz, 1H), 7.23–7.38 (m, 6H), 7.41–7.47 (m, 3H), 7.64–7.69 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  126.7 (d, *J* = 12.4 Hz), 127.9, 128.2, 128.3 (d, *J* = 11.5 Hz), 130.9, 131.4 (d, *J* = 2.9 Hz), 131.5 (d, *J* = 1.9 Hz), 131.6 (d, *J* = 9.6 Hz), 132.0 (d, *J* = 8.6 Hz), 132.1, 132.52, 132.54 (d, *J* = 2.9 Hz), 132.6 (d, *J* = 108.3 Hz), 133.2, 133.7 (d, *J* = 104.5 Hz), 134.6 (d, *J* = 12.4 Hz), 135.1, 138.2, 140.0 (d, *J* = 3.8 Hz), 148.8 (d, *J* = 6.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  29.31; HRMS *m*/*z* calcd for C<sub>32</sub>H<sub>23</sub>Cl<sub>2</sub>OP (M<sup>+</sup>) 524.0864, found 524.0859.

(*E*)-[2-{1,2-Bis[4-(trifluoromethyl)phenyl]ethenyl}phenyl]diphenylphosphine Oxide (3ae). Mp 79–80 °C (colorless powder), 146 mg (98%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.69 (s, 1H), 6.91 (d, *J* = 8.3 Hz, 2H), 7.19–7.39 (m, 13H), 7.44–7.48 (m, 3H), 7.62–7.67 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  124.1 (q, *J* = 272.2 Hz), 124.2 (q, *J* = 272.2 Hz), 124.8 (q, *J* = 3.8 Hz), 124.9 (q, *J* = 3.8 Hz), 127.0 (d, *J* = 12.4 Hz), 128.4 (d, *J* = 11.5 Hz), 128.8 (q, *J* = 32.6 Hz), 129.3 (q, *J* = 32.6 Hz), 129.7, 131.0, 131.58 (d, *J* = 9.6 Hz), 131.62 (d, *J* = 2.8 Hz), 131.7 (d, *J* = 2.9 Hz), 132.0 (d, *J* = 8.6 Hz), 132.1 (d, *J* = 101.6 Hz), 132.8, 133.5 (d, *J* = 104.5 Hz), 134.5 (d, *J* = 12.5 Hz), 140.1 (d, *J* = 1.9 Hz), 141.5 (d, *J* = 3.8 Hz), 143.0, 148.1 (d, *J* = 7.6 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  29.36; HRMS *m*/*z* calcd for C<sub>34</sub>H<sub>23</sub>F<sub>6</sub>OP (M<sup>+</sup>) \$92.1391, found \$92.1395.

(Z)-{2-[1,2-Di(2-thienyl)ethenyl]phenyl}diphenylphosphine Oxide (3af). Mp 188–189 °C (pale yellow powder), 24 mg (20%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.84 (dd, J = 3.7, 5.0 Hz, 1H), 6.88 (dd, J = 0.9, 3.7 Hz, 1H), 6.92–6.95 (m, 2H), 7.05 (d, J = 5.0 Hz, 1H), 7.21–7.25 (m, 1H), 7.31–7.47 (m, 11H), 7.71–7.77 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  126.0, 126.6 (d, J = 12.5 Hz), 126.8 (d, J= 13.4 Hz), 127.2, 128.3 (d, J = 12.4 Hz), 129.4, 130.0 (d, J = 3.9 Hz), 130.8, 130.9, 131.26, 131.27 (d, J = 102.6 Hz), 131.36 (d, J = 13.4 Hz), 131.44 (d, J = 3.9 Hz), 131.48 (d, J = 3.8 Hz), 131.51, 133.5 (d, J = 104.5 Hz), 134.9 (d, J = 13.4 Hz), 139.7, 140.5, 148.0 (d, J = 8.6 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  29.36; HRMS m/z calcd for C<sub>28</sub>H<sub>21</sub>OPS<sub>2</sub> (M<sup>+</sup>) 468.0771, found 468.0775.

(*E*)-Diphenyl[2-(1-phenylprop-1-en-2-yl)phenyl]phosphine Oxide (3ag). Oil, 80 mg (81%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.88 (d, *J* = 1.4 Hz, 3H), 6.38 (s, 1H), 6.99 (d, *J* = 7.3 Hz, 2H), 7.15 (t, *J* = 7.3 Hz, 1H), 7.22–7.53 (m, 12H), 7.69–7.74 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  20.2, 126.0 (d, *J* = 13.4 Hz), 126.3, 127.7, 128.2 (d, *J* = 12.4 Hz), 129.0, 129.7 (d, *J* = 9.6 Hz), 131.1 (d, *J* = 104.5 Hz), 131.2 (d, *J* = 1.9 Hz), 131.69 (d, *J* = 8.7 Hz), 131.72 (d, *J* = 2.9 Hz), 132.7, 133.7 (d, *J* = 104.5 Hz), 134.1 (d, *J* = 12.5 Hz), 136.8 (d, *J* = 3.8 Hz), 137.3, 151.3 (d, *J* = 8.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$ 28.77; HRMS *m*/*z* calcd for C<sub>27</sub>H<sub>23</sub>OP (M<sup>+</sup>) 394.1487, found 394.1485.

(*E*)-Diphenyl[2-(1-phenylhex-1-en-2-yl)phenyl]phosphine Oxide (3ah). Mp 104–105 °C (pale yellow powder), 94 mg (86%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.76 (t, *J* = 6.9 Hz, 3H), 1.13–1.30 (m, 4H), 2.51 (t, *J* = 7.3 Hz, 2H), 6.02 (s, 1H), 6.93 (d, *J* = 7.3 Hz, 2H), 7.13–7.34 (m, 6H), 7.37–7.41 (m, 4H), 7.45–7.53 (m, 3H), 7.69 (dd, *J* = 7.3, 11.9 Hz, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  13.9, 22.8, 30.5, 32.8, 126.0 (d, *J* = 12.4 Hz), 126.2, 127.7, 128.2 (d, *J* = 11.5 Hz), 128.7, 130.6 (d, *J* = 103.5 Hz), 131.0 (d, *J* = 9.5 Hz), 131.27, 131.34 (d, *J* = 2.8 Hz), 131.4 (d, *J* = 2.9 Hz), 131.9 (d, *J* = 8.6 Hz), 133.8 (d, *J* = 103.5 Hz), 134.0 (d, *J* = 12.5 Hz), 137.4, 143.2 (d, *J* = 3.8 Hz), 149.9 (d, *J* = 7.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  29.42; HRMS *m*/*z* calcd for C<sub>30</sub>H<sub>29</sub>OP (M<sup>+</sup>) 436.1956, found 436.1954.

(*E*)-[2-(1-Cyclopropyl-2-phenylethenyl)phenyl]diphenylphosphine Oxide (3ai). Mp 26–27 °C (pale yellow powder), 61 mg, (58%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.26 (dt, *J* = 5.8, 5.8 Hz, 2H), 0.55 (dt, *J* = 5.8, 5.8 Hz, 2H), 1.69 (m, 1H), 6.13 (s, 1H), 7.14–7.19 (m, 2H), 7.22–7.29 (m, 5H), 7.33–7.49 (m, 8H), 7.65–7.70 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  7.6, 14.7, 126.2 (d, *J* = 12.4 Hz), 126.3, 127.6, 128.1 (d, *J* = 12.4 Hz), 129.3, 130.8 (d, *J* = 9.5 Hz), 131.1 (d, *J* = 1.9 Hz), 131.29 (d, *J* = 2.8 Hz), 131.34 (d, *J* = 104.0 Hz), 132.0 (d, *J* = 9.6 Hz), 132.5, 133.8 (d, *J* = 105.0 Hz), 133.0 (d, *J* = 12.4 Hz), 137.1, 141.4 (d, *J* = 3.8 Hz), 147.2 (d, *J* = 8.6 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  29.04; HRMS *m*/*z* calcd for C<sub>29</sub>H<sub>25</sub>OP (M<sup>+</sup>) 420.1643, found 420.1640.

(E)-Diphenyl[2-(2-phenylethenyl)phenyl]phosphine Oxide (3aj).<sup>16</sup> Mp 169–170 °C (colorless powder), 57 mg (50%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.91 (d, J = 16.0 Hz, 1H), 7.17–7.24 (m, 7H), 7.42–7.54 (m, 7H), 7.68–7.73 (m, 4H), 7.80–7.84 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  126.6 (d, J = 12.5 Hz), 126.7, 126.8, 127.2 (d, J = 6.8 Hz), 127.8, 128.4, 128.5 (d, J = 12.5 Hz), 130.1 (d, J = 101.6 Hz), 131.3, 131.8 (d, J = 2.9 Hz), 131.9 (d, J = 9.6 Hz), 132.2 (d, J = 2.9 Hz), 132.9 (d, J = 103.5 Hz), 133.7 (d, J = 12.5 Hz), 137.0, 142.3 (d, J = 6.7 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  31.73; HRMS m/z calcd for C<sub>26</sub>H<sub>21</sub>OP (M<sup>+</sup>) 380.1330, found 380.1328.

(*E*)-Diphenyl[2-(2-phenylethenyl)phenyl]phosphine (4).<sup>16</sup> Mp 58–59 °C (pale yellow powder), 60 mg (66%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.88 (ddd, J = 0.9, 4.5, 7.7 Hz, 1H), 6.96 (d, J = 16.3 Hz, 1H), 7.14–7.37 (m, 17H), 7.71 (dd, J = 4.0, 7.7 Hz, 1H), 7.78 (dd, J = 4.0, 15.8 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  125.4 (d, J = 3.8 Hz), 126.7, 127.2, 127.5 (d, J = 17.2 Hz), 127.6, 128.5 (d, J = 2.9 Hz), 128.7 (d, J = 16.2 Hz), 129.0, 130.4 (d, J = 2.9 Hz), 133.5, 133.9, 134.1, 135.7 (d, J = 13.3 Hz), 136.4 (d, J = 9.5 Hz), 137.4, 141.9 (d, J = 21.9 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>)  $\delta$  –13.41; HRMS *m*/*z* calcd for C<sub>26</sub>H<sub>21</sub>P (M<sup>+</sup>) 364.1381, found 364.1378.

**Butyl 3-[2-(Diphenylphosphoryl)phenyl]propanoate (6).** Oil, 59 mg (58%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.90 (t, *J* = 7.3 Hz, 3H), 1.26–1.35 (m, 2H), 1.50–1.57 (m, 2H), 2.52 (t, *J* = 7.7 Hz, 2H), 3.19 (t, *J* = 7.7 Hz, 2H), 4.00 (t, *J* = 6.7 Hz, 2H), 7.07 (ddd, *J* = 1.2, 7.7, 13.9 Hz, 1H), 7.16 (ddt, *J* = 1.2, 2.6, 7.7 Hz, 1H), 7.36 (ddd, *J* = 0.7, 4.2, 7.7 Hz, 1H), 7.44–7.49 (m, 5H), 7.55 (dtt, *J* = 1.4, 1.4, 6.6 Hz, 2H), 7.65 (ddt, *J* = 1.4, 6.9, 11.9 Hz, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 13.7, 19.0, 29.7 (d, *J* = 5.1 Hz), 30.6, 35.6, 64.1, 125.7 (d, *J* = 12.4 Hz), 128.5 (d, *J* = 12.5 Hz), 130.97 (d, *J* = 10.3 Hz), 131.00 (d, *J* = 102.0 Hz), 131.8 (d, *J* = 2.9 Hz), 131.9 (d, *J* = 9.5 Hz), 132.2 (d, *J* = 8.0 Hz), 172.9; <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>) δ 31.20; HRMS *m*/z calcd for C<sub>25</sub>H<sub>28</sub>O<sub>3</sub>P (M+H<sup>+</sup>) 407.1776, found 407.1770.

## ASSOCIATED CONTENT

### **Supporting Information**

Copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra of products. This material is available free of charge via the Internet at http://pubs.acs.org.

# AUTHOR INFORMATION

#### **Corresponding Author**

\*E-mail: satoh@chem.eng.osaka-u.ac.jp; miura@chem.eng. osaka-u.ac.jp.

#### Notes

The authors declare no competing financial interest.

# ACKNOWLEDGMENTS

This work was supported by Grants-in-Aid from MEXT, JSPS, and JST, Japan.

#### REFERENCES

 (1) For example, see: (a) Zhang, Q.; Adachi, C.; Matsunami, S.; Sakagami, K. Jpn. Kokai Tokkyo Koho 120, JP 2013008806, 2013
 (b) Han, C.; Zhang, Z.; Xu, H.; Xie, G.; Li, J.; Zhao, Y.; Deng, Z.; Liu, S.; Yan, P. Chem.—Eur. J. 2013, 19, 141. (c) Han, C.; Zhang, Z.; Xu, H.; Yue, S.; Li, J.; Yan, P.; Deng, Z.; Zhao, Y.; Yan, P.; Liu, S. J. Am. Chem. Soc. 2012, 134, 19179. (d) Han, C.; Zhao, Y.; Xu, H.; Chen, J.; Deng, Z.; Ma, D.; Li, Q.; Yan, P. Chem.—Eur. J. 2011, 17, 5800.
 (e) Cai, X.; Padmaperuma, A. B.; Sapochak, L. S.; Vecchi, P. A.; Burrows, P. E. Appl. Phys. Lett. 2008, 92, 083308. (f) Vecchi, P. A.; Padmaperuma, A. B.; Qiao, H.; Sapochak, L. S.; Burrows, P. E. Org. Lett. 2006, 8, 4211. (g) Burrows, P. E.; Padmaperuma, A. B.; Sapochak, L. S.; Djurovich, P.; Thompson, M. E. Appl. Phys. Lett. 2006, 88, 183503. For a review, see: (h) Xiao, L.; Chen, Z.; Qu, B.; Luo, J.; Kong, S.; Gong, Q.; Kido, J. Adv. Mater. 2011, 23, 926.

(2) Lam, K.-H.; Chui, C.-H.; Gambari, R.; Wong, R. S.-M.; Cheng, G. Y.-M.; Lau, F.-Y.; Lai, P. B.-S.; Tong, S.-W.; Chan, K.-W.; Wong, W.-Y.; Chan, A. S.-C.; Tang, J. C.-O. *Eur. J. Med. Chem.* **2010**, *45*, 5527.

## The Journal of Organic Chemistry

(3) (a) Aoki, S.; Kotani, S.; Sugiura, M.; Nakajima, M. Chem. Commun. 2012, 48, 5524. (b) Shimoda, Y.; Kotani, S.; Sugiura, M.; Nakajima, M. Chem.—Eur. J. 2011, 17, 7992. (c) Kotani, S.; Hashimoto, S.; Nakajima, M. Tetrahedron 2007, 63, 3122.
(d) Ogawa, C.; Sugiura, M.; Kobayashi, S. Angew. Chem., Int. Ed. 2004, 43, 6491.

(4) Selected examples: (a) Busacca, C. A.; Raju, R.; Grinberg, N.; Haddad, N.; James-Jones, P.; Lee, H.; Lorenz, J. C.; Saha, A.; Senanayake, C. H. J. Org. Chem. 2008, 73, 1524. (b) Xie, J.-H.; Duan, H.-F.; Fan, B.-M; Cheng, X.; Wang, L.-X.; Zhou, Q.-L. Adv. Synth. Catal. 2004, 346, 625. (c) RajanBabu, T. V.; Nomura, N.; Jin, J.; Nandi, M.; Park, H.; Sun, X. J. Org. Chem. 2003, 68, 8431. (d) Baillie, C.; Xiao, J. Tetrahedron 2004, 60, 4159. (e) Imamoto, T.; Kikuchi, S.-I.; Miura, T.; Wada, Y. Org. Lett. 2001, 3, 87. (f) Yin, J.; Buchwald, S. L. J. Am. Chem. Soc. 2000, 122, 12051. (g) Imamoto, T.; Oshiki, T.; Onozawa, T.; Kusumoto, T.; Sato, K. J. Am. Chem. Soc. 1990, 112, 5244.

(5) Selected recent reviews for C-H functionalization: (a) Kozhushkov, S. I.; Ackermann, L. Chem. Sci. 2013, 4, 886. (b) Arockiam, P. B.; Bruneau, C.; Dixneuf, P. H. Chem. Rev. 2012, 112, 5879. (c) Colby, D. A.; Tsai, A. S.; Bergman, R. G.; Ellman, J. A. Acc. Chem. Res. 2012, 45, 814. (d) Engle, K. M.; Mei, T.-S.; Wasa, M.; Yu, J.-Q. Acc. Chem. Res. 2012, 45, 788. (e) Mitchell, E. A.; Peschiulli, A.; Lefevre, N.; Meerpoel, L.; Maes, B. U. W. Chem.-Eur. J. 2012, 18, 10092. (f) Song, G.; Wang, F.; Li, X. Chem. Soc. Rev. 2012, 41, 3651. (g) Patureau, F. W.; Wencel-Delord, J.; Glorius, F. Aldrichimica Acta 2012, 45, 31. (h) Cho, S. H.; Kim, J. Y.; Kwak, J.; Chang, S. Chem. Soc. Rev. 2011, 40, 5068. (i) Wencel-Delord, J.; Droge, T.; Liu, F.; Glorius, F. Chem. Soc. Rev. 2011, 40, 4740. (j) Kuninobu, Y.; Takai, K. Chem. Rev. 2011, 111, 1938. (k) Liu, C.; Zhang, H.; Shi, W.; Lei, A. Chem. Rev. 2011, 111, 1780. (1) Ackermann, L. Chem. Rev. 2011, 111, 1315. (m) Le Bras, J.; Muzart, J. Chem. Rev. 2011, 111, 1170. (n) Lyons, T. W.; Sanford, M. S. Chem. Rev. 2010, 110, 1147. (o) Colby, D. A.; Bergman, R. G.; Ellman, J. A. Chem. Rev. 2010, 110, 624. (p) Sun, C.-L.; Li, B.-J.; Shi, Z.-J. Chem. Commun. 2010, 46, 677. (q) Satoh, T.; Miura, M. Chem.-Eur. J. 2010, 16, 11212. (r) Karimi, B.; Behzadnia, H.; Elhamifar, D.; Akhavan, P. F.; Esfahani, F. K.; Zamani, A. Synthesis 2010, 1399. (s) Chen, X.; Engle, K. M.; Wang, D.-H.; Yu, J.-Q. Angew. Chem., Int. Ed. 2009, 48, 5094. (t) Daugulis, O.; Do, H.-Q.; Shabashov, D. Acc. Chem. Res. 2009, 42, 1074. (u) Li, C.-J. Acc. Chem. Res. 2009, 42, 335. (v) Park, Y. J.; Park, J.-W.; Jun, C.-H. Acc. Chem. Res. 2008, 41, 222. (w) Seregin, I. V.; Gevorgyan, V. Chem. Soc. Rev. 2007, 36, 1173. (x) Beccalli, E. M.; Broggini, G.; Martinelli, M.; Sottocornola, S. Chem. Rev. 2007, 107, 5318. (y) Alberico, D.; Scott, M. E.; Lautens, M. Chem. Rev. 2007, 107, 174. (z) Godula, K.; Sames, D. Science 2006, 312, 67. (6) Unoh, Y.; Hashimoto, Y.; Takeda, D.; Hirano, K.; Satoh, T.; Miura, M. Org. Lett. 2013, 15, 3258.

(7) Only one example of alkenylation of a ferrocenylphosphine oxide was reported, albeit with low efficiency: (a) Takebayashi, S.; Shibata, T. Organometallics **2012**, *31*, 4114. During the preparation of this manuscript, related oxidative coupling reactions involving P-OH directed C-H bond cleavage have been disclosed: (b) Seo, J.; Park, Y.; Jeon, I.; Ryu, T.; Park, S.; Lee, P. H. Org. Lett. **2013**, *15*, 3358. (c) Meng, X.; Kim, S. Org. Lett. **2013**, *15*, 1910. (d) Chan, L. Y.; Kim, S.; Ryu, T.; Lee, P. H. Chem. Commun. **2013**, *49*, 4682.

(8) For related Ru-catalyzed *ortho*-alkenylation utilizing other directing groups, see: (a) Hashimoto, Y.; Hirano, K.; Satoh, T.; Kakiuchi, F.; Miura, M. J. Org. Chem. 2013, 78, 638. (b) Hashimoto, Y.; Hirano, K.; Satoh, T.; Kakiuchi, F.; Miura, M. Org. Lett. 2012, 14, 2058. (c) Reddy, M. C.; Jeganmohan, M. Chem. Commun. 2013, 49, 481. (d) Cheng, K.; Yao, B.; Zhao, J.; Zhang, Y. Org. Lett. 2008, 10, 5309. (e) Kakiuchi, F.; Yamamoto, Y.; Chatani, N.; Murai, S. Chem. Lett. 1995, 681. For reviews concerning C–H bond cleavage/alkyne insertion, see: (f) de Mendoza, P.; Echavarren, A. M. Pure Appl. Chem. 2010, 82, 801. (g) Nakao, Y. Chem. Rec. 2010, 11, 242. (h) Kitamura, T. Eur. J. Org. Chem. 2009, 1111. (i) Vasil'ev, A. V. Russ. J. Org. Chem. 2009, 45, 1. (j) Jia, C.; Kitamura, T.; Fujiwara, Y. Acc. Chem. Res. 2001, 34, 633.

(9) For reviews, see: (a) Kakiuchi, F.; Kochi, T. Synthesis 2008, 3013.
(b) Kakiuchi, F.; Chatani, N. Adv. Synth. Catal. 2003, 345, 1077.
(c) Kakiuchi, F.; Murai, S. Acc. Chem. Res. 2002, 35, 826.

(10) Selected examples: (a) Li, Y.; Lu, L.-Q.; Das, S.; Pisiewicz, S.; Junge, K.; Beller, M. J. Am. Chem. Soc. 2012, 134, 18325.
(b) Kawakubo, H.; Kuroboshi, M.; Yano, T.; Kobayashi, K.; Kamenoue, S.; Akagi, T.; Tanaka, H. Synthesis 2011, 4091. (c) Berthod, M.; Favre-Réguillon, A.; Mohamad, J.; Mignani, G.; Docherty, G.; Lemaire, M. Synthesis 2007, 1545.

(11) Selected examples: (a) Anderson, K. W.; Ikawa, T.; Tundel, R. E.; Buchwald, S. L. J. Am. Chem. Soc. 2006, 128, 10694. (b) Anderson, K. W.; Tundel, R. E.; Ikawa, T.; Altman, R. A.; Buchwald, S. L. Angew. Chem., Int. Ed. 2006, 45, 6523. (c) Burgos, C. H.; Barder, T. E.; Huang, X.; Buchwald, S. L. Angew. Chem., Int. Ed. 2006, 45, 4321.

(12) It was recently reported that AcOH promotes the C-H bond activation of 2-phenylpyridine: (a) Flegeau, E. F.; Bruneau, C.; Dixneuf, P. H.; Jutand, A. J. Am. Chem. Soc. 2011, 133, 10161 and references therein. See also: (b) Boutadla, Y.; Davies, D. L.; Macgregor, S. A.; Poblador-Bahamonde, A. I. Dalton Trans. 2009, 5820. (c) Arockiam, P.; Poirier, V.; Fischmeister, C.; Bruneau, C.; Dixneuf, P. H. Green Chem. 2009, 11, 1871. (d) Ackermann, L.; Vicente, R.; Althammer, A. Org. Lett. 2008, 10, 2299. (e) Davies, D. L.; Al-Duaij, O.; Fawcett, J.; Giardiello, M.; Hilton, S. T.; Russell, D. R. Dalton Trans. 2003, 4132.

(13) Fryzuk, M. D.; Montgomery, C. D.; Rettig, S. J. Organometallics 1991, 10, 467.

(14) Novak, Z.; Nemes, P.; Kotschy, A. Org. Lett. 2004, 6, 4917.

(15) Liao, H.-H.; Liu, R.-S. Chem. Commun. 2011, 47, 1339.

(16) Butters, T.; Haller-Pauls, I.; Winter, W. Chem. Ber. 1982, 115, 578.